PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Epithelial ovarian cancer - Market size and forecast 2018-2023 • Germ cell ovarian cancer - Market size and forecast 2018-2023 • Stromal cell ovarian cancer - Market size and forecast 2018-2023 • Small cell ovarian cancer - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Clovis Oncology • F. Hoffmann-La Roche • Spectrum Pharmaceuticals • TESARO PART 14: APPENDIX • Research methodology List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline drugs in late-stage clinical trials Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Epithelial ovarian cancer - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Epithelial ovarian cancer - Year-over-year growth 2019-2023 (%) Exhibit 23: Germ cell ovarian cancer - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Germ cell ovarian cancer - Year-over-year growth 2019-2023 (%) Exhibit 25: Stromal cell ovarian cancer - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Stromal cell ovarian cancer - Year-over-year growth 2019-2023 (%) Exhibit 27: Small cell ovarian cancer - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Small cell ovarian cancer - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by type Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Decision framework Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: AstraZeneca - Vendor overview Exhibit 51: AstraZeneca - Product segments Exhibit 52: AstraZeneca - Organizational developments Exhibit 53: AstraZeneca - Geographic focus Exhibit 54: AstraZeneca - Key offerings Exhibit 55: Clovis Oncology - Vendor overview Exhibit 56: Clovis Oncology - Product segments Exhibit 57: Clovis Oncology - Organizational developments Exhibit 58: Clovis Oncology - Geographic focus Exhibit 59: Clovis Oncology - Key offerings Exhibit 60: F. Hoffmann-La Roche - Vendor overview Exhibit 61: F. Hoffmann-La Roche - Business segments Exhibit 62: F. Hoffmann-La Roche - Organizational developments Exhibit 63: F. Hoffmann-La Roche - Geographic focus Exhibit 64: F. Hoffmann-La Roche - Segment focus Exhibit 65: F. Hoffmann-La Roche - Key offerings Exhibit 66: Spectrum Pharmaceuticals - Vendor overview Exhibit 67: Spectrum Pharmaceuticals - Business segments Exhibit 68: Spectrum Pharmaceuticals - Organizational developments Exhibit 69: Spectrum Pharmaceuticals - Geographic focus Exhibit 70: Spectrum Pharmaceuticals - Key offerings Exhibit 71: TESARO - Vendor overview Exhibit 72: TESARO - Business segments Exhibit 73: TESARO - Organizational developments Exhibit 74: TESARO - Geographic focus Exhibit 75: TESARO - Key offerings Exhibit 76: Validation techniques employed for market sizing Exhibit 77: List of abbreviations  

AstraZeneca Clovis Oncology F. Hoffmann-La Roche Spectrum Pharmaceuticals TESARO